

---

# Fraunhofer Group for Life Sciences

Applied Science Dedicated to Life

**Cooperation on Pharmaceutical R&D between industry-public authorities-universities:  
Importance of effective collaboration**

**Istanbul, October 23rd**

---



# Joseph von Fraunhofer (1787-1826)

## Researcher – inventor – entrepreneur

An early pioneer with visions

### Researcher

- Discovery of »Fraunhofer Lines« in the sun spectrum

### Inventor


- new methods of lens processing

### Entrepreneur

- Head of royal glass factory



# Profile of Fraunhofer-Gesellschaft



- 66 institutes
- over 22,000 employees
- Budget of 2 billion euros

## Seven Fraunhofer Groups

- Information and Communication Technology ICT
- Life Sciences
- Microelectronics
- Light & Surfaces
- Production
- Materials and Components – MATERIALS
- Defense and Security VVS

# Creating Innovation at Fraunhofer

## Taking the Role of the Other:

- **Complementarity**
- **Gender and Diversity**
- **Intercultural Cooperation**

# Positioning – Fraunhofer Group for Life Sciences

## Research for human health and the environment

- Six strongly performing Fraunhofer institutes and a Fraunhofer research institution are collaborating in the Group
- 1707 employees
- Budget of 124 million euros (2013)
- Scientists, physicians, and engineers in close cooperation
- Synergies from cross-disciplinary cooperation
- applied research aimed at market-oriented solutions




# Increase the Potential:

**Systematic recording, evaluation of synergy potential, identification of overlapping developmental topics and involved players**

Pharmacogenetics,  
Pharmacogenomics

Stratification of clinical  
studies

*In vitro*  
diagnostics up  
to *in vivo*  
diagnostics  
(preventive  
medicine)




Body-area-  
networks

Biomarkers

Autologous tissue  
engineering

# Automated Tissue Engineering on Demand



## Values

### In-vitro-test systems

- Reduction of experiments with animals as part of REACH, cosmetic testing, and drug development
- Fulfillment of high quality standards standardization and automation of quality control for optimized clients' test results
- Sustainable use of resources non-destructing quality control methods



### Skin-transplants

- Quick and sufficient availability of high quality transplants

# Custom-Made Tissue Models – Tissue Engineering on Demand

## Goal

- Automation of a manually established tissue-engineering-method
- Increase production of human skin test models for in-vitro chemical, drug, and cosmetics tests

## Methods

- Re-engineering of every step of the laboratory procedure to automate the complete process
  - ➔ **Knowledge transfer and intensive dialogue between biologists and engineers**
- Construction and development of the complete facility including new processing methods and new tissue dissociation and bioreactor systems

## Results

- Optimized production of in-vitro-skin test models currently 5,000 units per months possible







# Biomarker Screening – Fraunhofer Foundation Project RIBOLUTION




Innovative Ribonucleic Acid-based  
Diagnostic Solutions for Personalized Medicine



# From a Small Association to the Leading Organization for Applied Research in Europe



# Networking of Players and Collaboration through System Research, e.g. Electromobility



# Business Units and Highlights

**BU 1**  
**Medical Translational Research and Biomedical Technology:**  
The Challenge of Innovative Diagnostics and Personalized Therapy

**BU 2**  
**Regenerative Medicine:**  
The Challenge of Qualified Biobanking and Controlled Self-Healing


**BU 3**  
**Healthy Foods:**  
The Challenge of High Consumer Acceptance and Disease Prevention



**BU 5**  
**Process, Chemical, and Herbicide Safety:**  
The Challenge of Environmental and Consumer Protection

**BU 4**  
**The New Potential of Biotechnology:**  
The Challenge to Learn from Nature for Industrial Exploitation



# BU 1 Medical Translational Research and Biomedical Technology: The Challenge of Innovative Diagnostics and Personalized Therapy



## Our responses


- innovative biomarkers for prognosis and therapy control
- wide variety of chip systems for in-vitro diagnostics – one component on the road to personalized therapy
- highly effective antibiotics from new sources such as insects
- improved imaging technology
- GMP platform with a wide range of expression systems
- ecological product design of pharmaceuticals

**Successful treatment through optimally tailored, personalized therapy**



# Translational Medicine: From Molecule to Patient

## Bio-Hybrid and Cell-Based Tests – Early Go/No-Go Decisions




### Target and drug discovery

- Databases: gene expression profiles
- High-throughput screening
- Array technologies
- Biochips: DNA chips, protein chips
- Cell-based assays and chips



### Target validation

- Animal transgenic and in-vitro 3-D human disease models
- Large-animal models
- Behavioral animal models
- Cardiovascular and neuronal organotypic models and disease models




### Lead optimization

- Structure optimization and humanization
- Aerosol generation
- High-content screening
- Human cell models
- Organotypic cell culture models

# GXP Platform: GLP – GMP – GCP

## APIs/Vaccines/Cell Therapeutics – System-independent Solutions – Clinical Studies Airways



### Safety pharmacology and toxicology

- GLP
- In-silico prediction ADME
- Molecular and functional imaging
- Nano- and microparticle systems
- Biomarkers of disease



### Manufacture of clinical investigational products

- Consulting on regulatory and economic aspects
- Evaluation of customer processes
- GMP facilities
- Compound libraries and high-throughput systems
- Expression systems




### Clinical trials of phases I and II

- GCP-compliant protocol development
- Toxicology and pharmacology
- Dose escalation studies in patients with malignant diseases
- Segmental lung challenge

# Pharmaceutical Biotechnology

- GMP- und non-GMP manufacturing of APIs
- Development of manufacturing processes
- Stability testing
- Validation of the manufacturing and purification process
- Aseptic filling of small quantities (Fill & Finish)





# Highlights GMP Services

- Development of robust and standardized production cell lines and manufacturing processes
- Manufacturing of active pharmaceutical ingredients (APIs) for pre-clinical and early-phase clinical trials
- Manufacturing of APIs, tissue engineering products, organoid test systems and cellular therapeutics for clinical studies
- Expression systems: mammalian cell cultures, yeasts, *E. coli*, plant cell cultures



# Manufacturing Processes for Biosimilar Drug Substances Developed at Fraunhofer

e.g.


EPO ✓

G-CSF ✓

β-INF ✓

**Individual molecules ↔ individual manufacturing process**

# Access Points for the Standardization of Antibody Manufacturing Processes



Modified from GB Kresse, Roche Diagnostics GmbH, 2009

# Elements of Fast Antibody Manufacturing Process Development at Fraunhofer


1. Standard cell line for the expression of different antibodies
2. Generic high cell density cultivation process
3. Robust and generic purification sequence
4. State of the art spectrum of analytical procedures

Implementation of generic elements in the antibody manufacturing process make process development independent from

- the target antibody and
- the starting materials

# Pre-clinical Studies

- Toxicity studies in rodents and non-rodents
- Reproduction toxicity studies
- Genetic and *In-vitro*-toxikology
- Inhalation toxikology/Pharmacology
- Immunology and immunotoxicity tests



# Clinical Trials Airways

- Clinical trials phase I and IIa
- Bronchoscopy with isolation of test samples
- Spirometry
- Fraunhofer Environmental Challenge Chambers ECC



# Balance, Harmony, and Empathy Research for Mankind

**Values must be  
internalized as needs**



**Needs must be  
internalized as  
values**

# Do not hesitate to contact us

We are pleased to help you find answers to any questions you might have or solutions you are looking for.

Please contact our Central Office:

**Dr. Claus-Dieter Kroggel**  
Head of Central Office

**Fraunhofer Group for Life Sciences**  
PHARIS Haus  
Feodor-Lynen-Str. 31  
30625 Hannover  
Germany

Phone +49 511 5466-440  
[claus.kroggel@vls.fraunhofer.de](mailto:claus.kroggel@vls.fraunhofer.de)



Dr. Claus-Dieter Kroggel  
Head of Central Office